Browse through Dermatology Advisor's home page to discover featured content, latest news, and treatment studies on topics in dermatology.

Dec 27, 2024 · Throughout 2024, the Food and Drug Administration (FDA) approved various new drugs and products, granted new indications for already approved drugs, and issued several new drug warnings for products indicated for dermatologic conditions.

Sep 10, 2024 · Dupilumab was more effective when compared with methotrexate (MTX) for the treatment of patients with atopic dermatitis (AD), and cyclosporin (CyA) was most effective in those with very severe disease, according to study findings published in the British Journal of Dermatology.. Researchers conducted a prospective observational cohort study to compare the real-world clinical effectiveness and ...

Mar 13, 2019 · Enjoying our content? Thanks for visiting Dermatology Advisor.We hope you’re enjoying the latest clinical news, full-length features, case studies, and more. You’ve viewed {{metering-count}} of {{metering-total}} articles this month.

Mar 22, 2024 · The American Academy of Dermatology (AAD) has issued updated guidelines for the clinical management of patients with acne vulgaris, which have been published in the Journal of the American Academy of Dermatology.. Systematic reviews to evaluate the effectiveness and safety of acne treatments approved by the United States Food and Drug Administration (FDA) were performed from May 2021 to ...

Oct 31, 2023 · The key endpoints assessed in the evaluated trials include percentages of patients achieving an Investigator Global Assessment score of 0 or 1 (IGA 0/1, indicating clear or near-clear skin), a 75% or 90% improvement in the Eczema Area and Severity Index (EASI 75 or EASI 90), and a 4-point or higher improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4).

Aug 23, 2024 · Included in the safety analysis were 2677 patients, of whom 60.2% were men. Mean (SD) patient age was 39.2 (13.4) years. The majority (82.4%) of patients continued treatment with dupilumab for at least 52 weeks and 12.5% continued treatment up to week 260 (5 years). Approximately half (48.4%) of patients completed both treatment and an end-of-study visit.

From March 17 to 21, 2023, dermatologists gathered for the American Academy of Dermatology (AAD) Annual Meeting, where they discussed the latest research on the treatment and management of a range of inflammatory skin diseases and other conditions. In this article, Emma Guttman-Yassky, MD, PhD, discusses the most exciting research on the treatment of moderate to severe atopic dermatitis ...

Oct 24, 2023 · The analysis included 13 clinical trials with a total of 7105 patients. The researchers evaluated 6 targeted therapies: abrocitinib (100 mg, 200 mg), baricitinib (2 mg, 4 mg), dupilumab 300 mg, lebrikizumab 250 mg, upadacitinib (15 mg, 30 mg), and tralokinumab 300 mg. All trials were placebo-controlled and generally comparable in terms of inclusion and exclusion criteria and potential ...

Jan 19, 2024 · Upadacitinib has a favorable aggregate response benefit compared with dupilumab and placebo for skin clearance and itch reduction among patients with moderate to severe atopic dermatitis, according to study results published in Dermatitis.. The findings are based on a post hoc analysis of data from the multicenter, phase 3 Heads Up (ClinicalTrials.gov Identifier: NCT03738397), Measure Up 1 ...